New program boosts PrEP adherence in Stimulant-Using men
NCT ID NCT04899024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a program called PARTI to help gay and bisexual men who use stimulants (like meth or cocaine) take their daily HIV prevention pill (PrEP) consistently. The program combined positive affect skills training with a smartphone-based reward system for taking PrEP. Researchers enrolled 239 men across multiple sites to see if this approach reduced HIV risk by improving medication adherence and reducing risky sex.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
behavioral intervention (PARTI: positive affect skills training plus contingency management)
What this could lead to
If successful, this approach could help high-risk men better adhere to PrEP and reduce new HIV infections.
What could go wrong
This is a completed behavioral study, not a drug trial. Results may not apply to all populations, and adherence improvements may not last long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDICATION ADHERENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States